Norwegian Cancer Precision Medicine Implementation Consortium
tor. 27. jan.
|Oslo Cancer Cluster Innovation Park
Register now: Cancer Crosslinks 2022
Cancer Crosslinks is an educational meeting series which promotes interactions between researchers and clinicians, and encourages translational and clinical research to support collaborations to advance the development of innovative cancer treatments.
Time & Location
27. jan. 2022, 11:30 – 16:00
Oslo Cancer Cluster Innovation Park, Ullernchausseen 64-66, 0379 Oslo, Norway
About the event
Register for the event here: Cancer Crosslinks 2022 – Oslo Cancer Cluster
For more information, go to January 2022 (cancercrosslinks.com)
Cancer Crosslinks 2022 will feature updates about the most recent progress in the understanding of tumor evolution and how it impacts cancer diagnostics and treatment:
Tracking Cancer Evolution through the Disease Course: Impact on Diagnostics and Treatment Decisions Today and Tomorrow, Mariam Jamal-Hanjani, UCL Cancer Institute London, UK Current and Future Methods of Predicting Response to Immunotherapy, David Rimm, Yale University School of Medicine, New Haven, USA Developing Early Phase Immunotherapy Trials / Neoadjuvant Treatments with Targeted & Immunotherapies, Martin Schuler, University Hospital Essen, Germany Update on Precision Therapy for Gynecological Cancers, Focus on Endometrial (Uterine) Cancer – Molecular Subtypes & Emerging Treatment Options (Including I-O), Angela George, Royal Marsden Hospital, London, UK Advances in Multiple Myeloma Treatment Using Proteasome Inhibitors (The Proteasome and Proteasome Inhibitors: From Biology to Clinical Impact), Christoph Driessen, Kantonsspital St. Gallen, Switzerland Gut Microbiome in the Immunotherapy Arena: From Biomarker to Therapeutics, Bertrand Routy, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Canada